Twist Bioscience has reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094) demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of Covid-19. The Coronavirus Immunotherapy Consortium (CoVIC), an academic-industry, non-profit collaborative research effort, […]